Find, compare & contact
Dichlorobenzyl alcohol API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Dichlorobenzyl alcohol is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Dichlorobenzyl alcohol or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Dichlorobenzyl alcohol API 1777-82-8?

Description:
Here you will find a list of producers, manufacturers and distributors of Dichlorobenzyl alcohol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Dichlorobenzyl alcohol 
Synonyms:
2,4-dichlorobenzenemethanol , 2,4-dichlorobenzyl alcohol , Alcohol diclorobencílico  
Cas Number:
1777-82-8 
DrugBank number:
DB13269 
Unique Ingredient Identifier:
1NKX3648J9

General Description:

Dichlorobenzyl alcohol, identified by CAS number 1777-82-8, is a notable compound with significant therapeutic applications. Dichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections. Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical. On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.

Indications:

This drug is primarily indicated for: Dichlorobenzyl alcohol in combination with is available in over-the-counter products used for symptomatic relief of acute sore throat and postoperative sore throat. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Dichlorobenzyl alcohol undergoes metabolic processing primarily in: Dichlorobenzyl alcohol is metabolized in the liver to form hippuric acid. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Dichlorobenzyl alcohol are crucial for its therapeutic efficacy: Dichlorobenzyl alcohol is released almost immediately from its formulation and reaches peak concentration after 3-4 minutes. The concentration in saliva after 120 minutes represents about 50% of the administered dose. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Dichlorobenzyl alcohol is an important consideration for its dosing schedule: This pharmacokinetic property has not been fully studied. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Dichlorobenzyl alcohol exhibits a strong affinity for binding with plasma proteins: This pharmacokinetic property has not been fully studied. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Dichlorobenzyl alcohol from the body primarily occurs through: In preclinical trials, dermal administration of dichlorobenzyl alcohol results in renal elimination of 90% of the administered dose. After metabolism, dichlorobenzyl alcohol is excreted in the urine. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Dichlorobenzyl alcohol is distributed throughout the body with a volume of distribution of: This pharmacokinetic property has not been fully studied. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Dichlorobenzyl alcohol is a critical factor in determining its safe and effective dosage: This pharmacokinetic property has not been fully studied. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Dichlorobenzyl alcohol exerts its therapeutic effects through: In vitro studies with the combination of dichlorobenzyl alcohol and amylmetacresol have shown a virucidal against a number of viruses associated with the common cold which is observed by a reduction in the viral load. In clinical trials, administration of dichlorobenzyl alcohol lozenges has been shown to generate a reduced throat soreness and to provide pain relief and relief from difficulty in swallowing 5 minutes after administration. This effect can last for even 2 hours. The relief effect was shown to reach a steady-state after 45 minutes. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Dichlorobenzyl alcohol functions by: The use of dichlorobenzyl alcohol has been related to its antibacterial, antiviral and local anesthetic properties. The local anesthetic action of dichlorobenzyl alcohol is thought to be due to a reduced sodium channel blockade. The antiseptic mechanism of action of dichlorobenzyl alcohol is not fully understood but it is thought to be related to a denaturation of external proteins and rearrangement of the tertiary structure proteins. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Dichlorobenzyl alcohol belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it, classified under the direct parent group Dichlorobenzenes. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Halobenzenes subclass.

Categories:

Dichlorobenzyl alcohol is categorized under the following therapeutic classes: Alcohols, Anti-Infective Agents, Local, Benzene Derivatives, Benzyl Compounds, Drugs that are Mainly Renally Excreted, Throat Preparations. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Dichlorobenzyl alcohol include:

  • Water Solubility: Slightly Soluble
  • Melting Point: 55-58 ºC
  • Boiling Point: 150 ºC
  • logP: 2.36

Dichlorobenzyl alcohol is a type of Anti-infective Agents


Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.

Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.

The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.

The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.

In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.